Key Highlights

  • Arcadia Biosciences (NASDAQ:RKDA) quoted USD 0.1711, up 8.15%, in premarket trading on November 5, 2026, per the premarket quote.
  • The 10-Q for the quarter ended June 30, 2026 reports Revenue of USD 1.44 million and a net loss of USD 6.27 million, with cash of USD 4.18 million.
  • The filing says cash will not cover requirements for 12 months and raises substantial doubt about the ability to continue as a going concern.
  • The proposed combination with Roosevelt Resources was terminated on December 26, 2025 and about 2.7 million Above Food shares are carried at zero.

Latest Filing Frames the Move

Arcadia Biosciences (NASDAQ:RKDA) is quoted higher in premarket trading on November 5, 2026, and the most recent major update is its Quarterly Report for the period ended June 30, 2026. Revenue was USD 1.44 million, essentially flat against USD 1.46 million a year earlier, and USD 2.54 million for the six months compared with USD 2.66 million. The net loss was USD 6.27 million for the quarter and USD 10.65 million for the half. Cash and cash equivalents were USD 4.18 million at June 30, 2026. Management has built the story around the Zola coconut water brand, lower operating expenses and the absence of long-term debt.

Going Concern, Deal History and Investment Holdings

The 10-Q states that existing cash will not be sufficient for at least the next 12 months and that this raises substantial doubt about the company's ability to continue as a going concern. It names financings or asset sales as Options and warns of possible Liquidation or Bankruptcy proceedings if funding is not found. On December 26, 2025 Roosevelt Resources, LP, an oil and Natural Gas company, ended the Securities Exchange Agreement behind a proposed Business combination, and Arcadia said it would resume evaluating strategic alternatives. Chief Executive Officer T.J. Schaefer described the company as an attractive candidate for a Merger or other strategic transaction. Arcadia also holds about 2.7 million shares of Above Food Ingredients, whose Nasdaq trading was suspended and which now quote over the counter. The filing carries them at zero as of June 30, 2026 after unrealized losses of about USD 2.8 million in the quarter and USD 4.3 million for the half.

Thin Liquidity, Listing Pressure and What to Watch

Published market data shows the Market Value of listed securities at about USD 381.1 thousand against a USD 5.00 million Nasdaq floor for 65 consecutive business days, and a closing bid of USD 0.1582. The same data says the Securities and Exchange Commission stayed the relevant rule on July 29, 2026, which limits delisting determinations under it while the stay holds. These figures come from one data page and are treated as approximate. At this price level a small number of trades can move the quote, spreads can be wide and a premarket gain of 8.15% can reverse quickly. Watch for a new financing, a strategic transaction, any Nasdaq notice in an 8-K, and the next quarterly report.

Where Things Stand

The 8.15% premarket gain at Arcadia Biosciences (NASDAQ:RKDA) looks like a trading reaction in a very thin, very low-priced stock, since the latest filing offers more caution than reassurance. Revenue is flat at about USD 1.44 million a quarter, losses are running at more than four times that figure, and the company has told investors there is substantial doubt about its ability to continue. The offsetting points are the cash balance of USD 4.18 million, the absence of long-term Debt and the stated openness to a merger. The next catalysts are a financing, a strategic deal or a listing notice.